NR1H4 and colitis: In conclusion, the results of the present study indicate that the synthetic FXR agonist nelumal A effectively attenuated colitis and suppressed colitis-related tumourigenesis presumably through the reduction in bile acid synthesis and decline in the inflammation and oxidative damage.